#1 Clinical Trials Search in Europe

Trametinib Dimethyl Sulfoxide

Trametinib Dimethyl Sulfoxide, also known as Mekinist, is being studied in several clinical trials as a potential treatment for various types of cancer. This article explores the ongoing research into this drug’s effectiveness, particularly when used in combination with other medications, for treating advanced cancers with specific genetic mutations. The trials aim to evaluate its safety, efficacy, and potential to improve patient outcomes in conditions like melanoma, lymphoma, and other solid tumors.

Table of Contents

What is Trametinib?

Trametinib Dimethyl Sulfoxide, commonly known as Trametinib, is a medication used in the treatment of various types of cancer. It is also known by brand names such as Mekinist, Meqsel, and Spexotras[1]. Trametinib belongs to a class of drugs called MEK inhibitors, which work by blocking specific proteins involved in cancer cell growth[1].

How Trametinib Works

Trametinib works by inhibiting (blocking) proteins called MEK1 and MEK2. These proteins are part of a pathway in cells that controls growth and survival. In many types of cancer, this pathway is overactive, leading to uncontrolled cell growth. By blocking MEK1 and MEK2, Trametinib can help slow down or stop the growth of cancer cells[1].

Conditions Treated with Trametinib

Trametinib is used to treat several types of cancer, particularly those with specific genetic mutations. Some of the conditions it’s used for include:

  • Melanoma: A type of skin cancer, especially in cases with BRAF V600 mutations[2]
  • Non-small cell lung cancer: A common type of lung cancer[3]
  • Anaplastic thyroid cancer: An aggressive form of thyroid cancer[3]
  • Erdheim-Chester Disease: A rare blood disorder, especially in cases with BRAF V600 mutations[4]
  • Low-grade ovarian cancer or peritoneal cancer: Cancers affecting the ovaries or the lining of the abdominal cavity[5]

Trametinib in Combination Therapy

Trametinib is often used in combination with other cancer medications, particularly with drugs that target the BRAF protein. One common combination is Trametinib with Dabrafenib, another targeted therapy. This combination has shown effectiveness in treating several types of cancer, including:

  • BRAF V600 mutation-positive melanoma[2]
  • BRAF V600 mutation-positive Erdheim-Chester Disease[4]
  • Certain types of high-grade gliomas (brain tumors) with BRAF V600 mutations[6]

The combination of these drugs can be more effective than using either drug alone in some cases, as it targets the cancer growth pathway at multiple points[3].

How Trametinib is Administered

Trametinib is typically taken orally (by mouth) once daily. It’s usually given in 28-day cycles, meaning you take it every day for 28 days, then repeat the cycle[1]. The exact dosage and schedule can vary depending on your specific condition, other medications you’re taking, and how your body responds to the treatment. Always follow your doctor’s instructions carefully when taking Trametinib.

Potential Side Effects

Like all medications, Trametinib can cause side effects. Some common side effects may include:

  • Skin rash or other skin problems
  • Diarrhea
  • Fatigue
  • Swelling (edema)
  • Nausea

More serious side effects can occur, such as heart problems, eye problems, or lung inflammation. It’s important to report any side effects to your healthcare team promptly[6].

Ongoing Research and Clinical Trials

Researchers continue to study Trametinib to understand its full potential in cancer treatment. Several clinical trials are ongoing, investigating its use in various types of cancer and in combination with other treatments. For example:

  • A study is looking at the combination of Trametinib, Dabrafenib, and Hydroxychloroquine in advanced melanoma[2]
  • Another trial is studying Trametinib with Dabrafenib after radiation therapy in newly-diagnosed high-grade gliomas[6]
  • Researchers are also investigating Trametinib in comparison to standard treatments for low-grade ovarian or peritoneal cancer[5]

These ongoing studies help doctors and researchers better understand how to use Trametinib effectively and safely in different types of cancer.

Aspect Details
Drug Name Trametinib Dimethyl Sulfoxide (Mekinist)
Mechanism of Action Inhibits MEK1 and MEK2 proteins, potentially stopping cancer cell growth
Cancer Types Studied Advanced lymphoma, malignant solid neoplasms, melanoma, high-grade glioma
Genetic Mutations Targeted BRAF V600, NF1, GNAQ, GNA11 mutations
Common Combination Often used with Dabrafenib
Administration Oral, once daily
Treatment Cycle Typically 28 days
Primary Outcomes Measured Objective response rate, progression-free survival, overall survival
Safety Monitoring Adverse events, toxicity profile
Potential Benefits May shrink tumors or stop their growth in specific cancer types

FAQ

  • What is Trametinib Dimethyl Sulfoxide? Trametinib Dimethyl Sulfoxide, also known as Mekinist, is a drug that blocks proteins called MEK1 and MEK2, which may be needed for cancer cell growth. It is being studied in clinical trials for its potential to treat various types of cancer, especially those with specific genetic mutations.
  • What types of cancer are being studied with Trametinib? Trametinib is being studied in clinical trials for various cancers, including advanced lymphoma, malignant solid neoplasms, melanoma, and high-grade glioma. It is particularly being investigated in cancers with specific genetic mutations such as BRAF V600, NF1, GNAQ, and GNA11 mutations.
  • How is Trametinib administered in these clinical trials? In most of the clinical trials, Trametinib is administered orally (by mouth) once daily. It is often given in combination with other drugs, such as Dabrafenib, and the treatment cycles typically repeat every 28 days.
  • What are the main objectives of these clinical trials? The main objectives of these trials include assessing the safety and efficacy of Trametinib, often in combination with other drugs. Researchers are looking at factors such as objective response rates, progression-free survival, overall survival, and the incidence of adverse events.
  • Are there any specific genetic mutations that Trametinib targets? Yes, many of the clinical trials are focusing on cancers with specific genetic mutations. These include BRAF V600 mutations, NF1 mutations, and GNAQ or GNA11 mutations. The presence of these mutations may influence how effective Trametinib is as a treatment.

Ongoing Clinical Trials on Trametinib Dimethyl Sulfoxide

  • Long-term study of dabrafenib and trametinib in children and adolescents with cancers that have V600 mutation

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark Finland France Germany +4

  • Study on Trametinib Dimethyl Sulfoxide for Children with Refractory Histiocytosis Not Responding to Conventional Treatment

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland

  • Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia France Germany Hungary Italy +2

  • Study on the Effectiveness and Safety of Naporafenib Combinations in Patients with Previously Treated Unresectable or Metastatic Melanoma

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy

  • Study of JDQ443 and Ribociclib in Combination for Adult Patients with Advanced Solid Tumors with KRAS G12C Mutation

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Italy Spain

Glossary

  • Trametinib Dimethyl Sulfoxide: A drug that inhibits MEK1 and MEK2 proteins, potentially stopping cancer cell growth. It's being studied in various cancer types, especially those with specific genetic mutations.
  • Dabrafenib: A drug often used in combination with Trametinib that targets the BRAF protein, another enzyme involved in cancer cell growth.
  • BRAF V600 mutation: A specific genetic change in the BRAF gene that can drive cancer growth, particularly in melanoma and other cancers.
  • MEK1 and MEK2: Proteins involved in cell signaling pathways that regulate cell growth and survival. They are targets of Trametinib.
  • Objective Response Rate (ORR): The proportion of patients whose tumors decrease in size (partial response) or disappear completely (complete response) due to treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with the disease without it worsening.
  • Overall Survival (OS): The length of time from either the date of diagnosis or the start of treatment that patients are still alive.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Adverse Events: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Erdheim-Chester Disease: A rare form of non-Langerhans cell histiocytosis, a group of diseases where certain white blood cells accumulate in various tissues and organs.

References

  1. https://clinicaltrials.gov/study/NCT04439318
  2. https://clinicaltrials.gov/study/NCT04527549
  3. https://clinicaltrials.gov/study/NCT04439292
  4. https://clinicaltrials.gov/study/NCT02281760
  5. https://clinicaltrials.gov/study/NCT02101788
  6. https://clinicaltrials.gov/study/NCT03919071